JP2019528739A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528739A5 JP2019528739A5 JP2019515294A JP2019515294A JP2019528739A5 JP 2019528739 A5 JP2019528739 A5 JP 2019528739A5 JP 2019515294 A JP2019515294 A JP 2019515294A JP 2019515294 A JP2019515294 A JP 2019515294A JP 2019528739 A5 JP2019528739 A5 JP 2019528739A5
- Authority
- JP
- Japan
- Prior art keywords
- aptamer
- polynucleotide
- nucleotides
- stem
- nucleotide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 27
- 125000003729 nucleotide group Chemical group 0.000 claims 27
- 108091023037 Aptamer Proteins 0.000 claims 23
- 108091033319 polynucleotide Proteins 0.000 claims 16
- 239000002157 polynucleotide Substances 0.000 claims 16
- 102000040430 polynucleotide Human genes 0.000 claims 16
- 239000000729 antidote Substances 0.000 claims 6
- 230000004048 modification Effects 0.000 claims 6
- 238000012986 modification Methods 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 239000000539 dimer Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000013638 trimer Substances 0.000 claims 4
- 101150045640 VWF gene Proteins 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000003381 stabilizer Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 claims 1
- 101100156611 Homo sapiens VWF gene Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102100032442 Protein S100-A8 Human genes 0.000 claims 1
- 229940075522 antidotes Drugs 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022176918A JP7675990B2 (ja) | 2016-09-16 | 2022-11-04 | フォン・ビルブラント因子（ｖｗｆ）標的薬剤およびそれを用いる方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662395642P | 2016-09-16 | 2016-09-16 | |
| US62/395,642 | 2016-09-16 | ||
| PCT/US2017/052063 WO2018053427A1 (en) | 2016-09-16 | 2017-09-18 | Von willebrand factor (vwf)-targeting agents and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022176918A Division JP7675990B2 (ja) | 2016-09-16 | 2022-11-04 | フォン・ビルブラント因子（ｖｗｆ）標的薬剤およびそれを用いる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528739A JP2019528739A (ja) | 2019-10-17 |
| JP2019528739A5 true JP2019528739A5 (enExample) | 2020-11-12 |
| JP7560821B2 JP7560821B2 (ja) | 2024-10-03 |
Family
ID=61619783
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515294A Active JP7560821B2 (ja) | 2016-09-16 | 2017-09-18 | フォン・ビルブラント因子（ｖｗｆ）標的薬剤およびそれを用いる方法 |
| JP2022176918A Active JP7675990B2 (ja) | 2016-09-16 | 2022-11-04 | フォン・ビルブラント因子（ｖｗｆ）標的薬剤およびそれを用いる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022176918A Active JP7675990B2 (ja) | 2016-09-16 | 2022-11-04 | フォン・ビルブラント因子（ｖｗｆ）標的薬剤およびそれを用いる方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10889816B2 (enExample) |
| EP (1) | EP3512526A4 (enExample) |
| JP (2) | JP7560821B2 (enExample) |
| CN (1) | CN109982707A (enExample) |
| WO (1) | WO2018053427A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10660973B2 (en) | 2015-04-28 | 2020-05-26 | Duke University | Thrombus imaging aptamers and methods of using same |
| CN112384236A (zh) * | 2018-03-27 | 2021-02-19 | Umc乌得勒支控股有限公司 | 用于治疗微血管血栓形成的靶向溶栓 |
| JP2022044843A (ja) * | 2018-12-11 | 2022-03-18 | 日産化学株式会社 | 解毒剤 |
| EP4100121A4 (en) * | 2020-02-04 | 2024-04-10 | Band Therapeutics, LLC | REGULATION OF THE VON WILLEBRAND FACTOR (VWF) |
| CN113244381A (zh) * | 2021-06-02 | 2021-08-13 | 苏州大学 | 游离的血红蛋白及其衍生物抗血小板聚集的应用 |
| WO2025076424A1 (en) * | 2023-10-06 | 2025-04-10 | Ohio State Innovation Foundation | Aptamer bb-031 and methods of using thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770198A (en) | 1988-05-18 | 1998-06-23 | The Research Foundation Of The State Of New York | Platelet-specific chimeric 7E3 immunoglobulin |
| US6261774B1 (en) | 1990-06-11 | 2001-07-17 | Gilead Sciences, Inc. | Truncation selex method |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5756291A (en) | 1992-08-21 | 1998-05-26 | Gilead Sciences, Inc. | Aptamers specific for biomolecules and methods of making |
| EP0668766A1 (en) | 1992-10-23 | 1995-08-30 | University Of Massachusetts Medical Center | Small molecule inhibition of rna/ligand binding |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| US6780850B1 (en) | 1999-06-22 | 2004-08-24 | Triumf | Extending the lifetime of anticoagulant oligodeoxynucleotide aptamers in blood |
| GB0014136D0 (en) | 2000-06-10 | 2000-08-02 | Astrazeneca Ab | Combination therapy |
| GB0014134D0 (en) | 2000-06-10 | 2000-08-02 | Astrazeneca Ab | Combination therapy |
| US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
| AU2001296305B2 (en) | 2000-09-26 | 2007-12-06 | Duke University | RNA aptamers and methods for identifying the same |
| PT1401853E (pt) | 2001-05-25 | 2010-12-07 | Univ Duke | Modulador de oligonucleotídeos |
| AUPR604101A0 (en) | 2001-06-29 | 2001-07-26 | Unisearch Limited | Aptamers |
| US20070071744A1 (en) | 2002-06-07 | 2007-03-29 | Gotz Munch | Agents which bind to epitopes of glycoprotein VI |
| EP1546183A4 (en) * | 2002-09-23 | 2008-06-18 | Du Pont | ISOLATION AND USE OF RYANODINE RECEPTORS |
| US20060193821A1 (en) | 2004-03-05 | 2006-08-31 | Diener John L | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| CN103045601B (zh) | 2004-04-22 | 2015-04-01 | 雷加多生物科学公司 | 改良的凝血因子调节物 |
| US7566701B2 (en) | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
| EP1791557A4 (en) | 2004-09-07 | 2009-09-23 | Archemix Corp | MEDICAL CHEMISTRY USING APTAMERS |
| MX2007002772A (es) | 2004-09-07 | 2008-03-05 | Archemix Corp | Aptameros para el factor de von willebrand y su uso como agentes terapeuticos para la enfermedad trombotica. |
| TWI403334B (zh) | 2004-12-23 | 2013-08-01 | Merck Sharp & Dohme | 包含生物素殘基之抗血栓雙重抑制劑 |
| US7795009B2 (en) | 2005-06-15 | 2010-09-14 | Saint Louis University | Three-component biosensors for detecting macromolecules and other analytes |
| US20100076060A1 (en) | 2005-09-15 | 2010-03-25 | Duke University | Aptamers as agonists |
| EP1931803A2 (en) | 2005-09-15 | 2008-06-18 | Duke University | Focused libraries, functional profiling, laser selex and deselex |
| WO2007140000A2 (en) | 2006-05-26 | 2007-12-06 | Regado Biosciences, Inc. | Administration of the reg1 anticoagulation system |
| WO2008066621A2 (en) | 2006-10-19 | 2008-06-05 | Duke University | Reversible platelet inhibition |
| US8790924B2 (en) | 2006-10-19 | 2014-07-29 | Duke University | Reversible platelet inhibition |
| US8372427B2 (en) | 2007-03-05 | 2013-02-12 | Abbott Cardiovascular Systems Inc. | Therapeutic composition with enhanced endothelium targeting |
| WO2008121354A1 (en) | 2007-03-30 | 2008-10-09 | Duke University | A method of modulating the activity of a nucleic acid molecule |
| US20090203766A1 (en) * | 2007-06-01 | 2009-08-13 | Archemix Corp. | vWF aptamer formulations and methods for use |
| JP5896742B2 (ja) | 2008-08-22 | 2016-03-30 | バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ | 出血性障害を処置するための方法 |
| AU2010256511B2 (en) | 2009-06-03 | 2016-01-14 | Tobira Therapeutics, Inc. | Nucleic acid modulators of glycoprotein VI |
| KR20230098713A (ko) | 2009-06-10 | 2023-07-04 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| IN2012DN02345A (enExample) | 2009-09-16 | 2015-08-21 | Univ Duke | |
| US9061043B2 (en) | 2010-10-13 | 2015-06-23 | Duke University | Aptamers to glycoprotein VI |
| WO2012149024A2 (en) * | 2011-04-28 | 2012-11-01 | Mayo Foundation For Medical Education And Research | Dna aptamers for promoting remyelination |
| WO2012151575A2 (en) | 2011-05-05 | 2012-11-08 | Duke University | A method of controlling coagulation |
| US20140348755A1 (en) | 2011-09-21 | 2014-11-27 | Nplex Laboratory Inc. | Targeted nanoparticles joined to reporter molecules through multiple mechanisms |
| EP2912182B1 (en) * | 2012-10-23 | 2021-12-08 | Caris Science, Inc. | Aptamers and uses thereof |
| WO2014169049A1 (en) | 2013-04-09 | 2014-10-16 | Duke University | 2' fluoro-modified rnas as immunostimulators |
| US20160130585A1 (en) * | 2013-05-28 | 2016-05-12 | The Johns Hopkins University | Aptamers for the treatment of sickle cell disease |
| KR20170055474A (ko) | 2014-07-31 | 2017-05-19 | 아카데미아 시니카 | 길항 pd-1 압타머 및 암 요법 관련 적용에서의 그의 적용 |
| US10660973B2 (en) | 2015-04-28 | 2020-05-26 | Duke University | Thrombus imaging aptamers and methods of using same |
-
2017
- 2017-09-18 US US16/334,307 patent/US10889816B2/en active Active
- 2017-09-18 JP JP2019515294A patent/JP7560821B2/ja active Active
- 2017-09-18 WO PCT/US2017/052063 patent/WO2018053427A1/en not_active Ceased
- 2017-09-18 CN CN201780069446.1A patent/CN109982707A/zh active Pending
- 2017-09-18 EP EP17851722.3A patent/EP3512526A4/en active Pending
-
2021
- 2021-01-11 US US17/146,147 patent/US11965160B2/en active Active
-
2022
- 2022-11-04 JP JP2022176918A patent/JP7675990B2/ja active Active
-
2024
- 2024-03-29 US US18/622,413 patent/US20240318178A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019528739A5 (enExample) | ||
| Beauté et al. | Photo-triggered polymer nanomedicines: From molecular mechanisms to therapeutic applications | |
| JP2018522563A5 (enExample) | ||
| JP2018503668A5 (enExample) | ||
| Ibraheem et al. | Administration strategies for proteins and peptides | |
| JP2016504362A5 (enExample) | ||
| JP2017534638A5 (enExample) | ||
| CY1121910T1 (el) | Φαρμακευτικο παρασκευασμα που περιεχει παραγωγο διυδροκιναζολινης με αντιϊικη δραση | |
| JP2018511327A5 (enExample) | ||
| JP2015513897A5 (enExample) | ||
| MX2017012506A (es) | Composicion farmaceutica para la prevencion y tratamiento de enfermedades del ojo que contiene, como ingrediente activo, una proteina de fusion en la cual el peptido que penetra el tejido y la preparacion del factor de crecimiento endotelial antivascular se fusionan. | |
| JP2017532965A5 (enExample) | ||
| JP2011502479A5 (enExample) | ||
| JP2015518818A5 (enExample) | ||
| JP7675990B2 (ja) | フォン・ビルブラント因子（ｖｗｆ）標的薬剤およびそれを用いる方法 | |
| BR112019002394A2 (pt) | citocina fundida com fc heterodimérico e composição farmacêutica compreendendo o mesmo | |
| JP2013136622A5 (enExample) | ||
| JP2016521712A5 (enExample) | ||
| JP2014526881A5 (enExample) | ||
| JP2015128433A5 (enExample) | ||
| MY178445A (en) | Novel antibody binding to tfpi and composition comprising the same | |
| JP2019508175A5 (enExample) | ||
| JP2018517767A5 (enExample) | ||
| SI2968442T1 (en) | New stable pentadecapeptide salts, a process for their preparation, their use in the manufacture of pharmaceutical preparations and their use in therapy | |
| JP2011504736A5 (enExample) |